About me
Jorge Santos da Silva, PhD, is Chief Executive Officer and Co-Founder of MoonLake Immunotherapeutics. He also serves as an Executive Director in the Board of MoonLake Immunotherapeutics. Jorge founded MoonLake in 2021 and took it public on NASDAQ (ticker: MLTX) in 2022, in one of the most successful SPAC-related transactions on record. MoonLake is a late clinical-stage company developing innovative NanobodiesTM to treat chronic auto immune disease and is invested by several blue chip US investors, and with a market cap of 3bn+. Jorge previously served as Senior Partner at McKinsey & Company and as leader of its Global Pharmaceuticals and Medical Products Practice. Jorge spent almost 15 years at McKinsey & Company, from 2007, helping the largest global Pharma companies and the largest global Biotechs to define their corporate, business and portfolio strategies, drug development roadmaps and drug launches, as well as their organizational structures. He worked across the US, Europe, Asia and Latin America. He started McKinsey’s Biosimilars & Biologics Practice as well as its Biotech Practice and led those for a decade, granting him a unique view on starting and growing biotechs and on developing complex drugs for chronic disease. He also runs FirstLight Investments, a small cap fund and serves as Professor and Board Member of the School of Medicine. Jorge is a BSc. in Molecular Biology, MSc. In Cellular Biology and a Ph.D. in Neuroscience. He obtained his degrees in the UK, Germany and Italy and the US. Afterwards, he ran his research programs, funded by the NIH, EMBO and HFSP, at Cold Spring Harbor Labs in NY, US. During his academic tenure, Jorge published a wealth of peer-reviewed papers in the highest impact-factor journals in his fields of research.
